This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (1)  • Contact me when this article is cited  Related Content  • Related letters  • Similar articles in JAMA  Topic Collections  • Medical Practice  • Law and Medicine  • Public Health, Other  • Quality of Care  • Patient Safety/ Medical Error  • Drug Therapy  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

The FDA, Preemption, and the Public's Health

Lawrence O. Gostin, JD

JAMA. 2009;301(19):2036-2037.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In 2008, the US Supreme Court held that the Medical Device Amendments (MDA) bar common law claims challenging the safety or effectiveness of a medical device approved by the US Food and Drug Administration (FDA).¹ Riegel v Medtronic Inc² had broad implications for patient safety because it removed all means of judicial recourse for most consumers injured by defective medical devices. At that time, the Supreme Court agreed to hear Wyeth v Levine,³ which consumer safety advocates feared would similarly preempt pharmaceutical lawsuits with far-reaching effects. There are 11 000 FDA-regulated drugs, with nearly 100 more approved each year,⁴ and patients would have no safety net in the event the FDA fails to detect and correct safety hazards. In a recent 6-3 decision, the Supreme Court ruled that the FDA's approval of a drug label does not preempt a state law product liability claim charging the . . . [Full Text of this Article]

Preemption of State Tort Liability

Author Affiliations: O’Neill Institute for National and Global Health Law, Georgetown University, Washington, DC.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTERS

Tort Claims and Federal Regulation of Medical Devices vs Pharmaceuticals
Michael Green
JAMA. 2009;302(11):1169.
EXTRACT | FULL TEXT  

Tort Claims and Federal Regulation of Medical Devices vs Pharmaceuticals—Reply
Lawrence O. Gostin
JAMA. 2009;302(11):1169-1170.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Tort Claims and Federal Regulation of Medical Devices vs Pharmaceuticals
Green
JAMA 2009;302:1169-1169.
FULL TEXT